SoftBank Group has announced a strategic joint venture with Tempus AI, an AI-driven medical data analysis company. Revealed by SoftBank’s CEO Masayoshi Son, this partnership signifies another major investment in AI by SoftBank, following a $200 million investment in Tempus earlier this year. Tempus, known for its genomic testing and AI-powered treatment recommendations, aims to bring its advanced healthcare services to Japan. The joint venture, set to close in July, involves a $93 million investment from each party. Google has also shown substantial support for Tempus, bolstering its AI capabilities and contributing to its growth. Tempus recently went public on Nasdaq, achieving a market cap of $6 billion and collaborating with top pharmaceutical companies and academic medical centers. This partnership with SoftBank positions Tempus AI as a leader in AI-powered healthcare services, promising significant advancements in medical diagnostics and treatment in Japan.
SoftBank Partners with Tempus AI to Revolutionize Healthcare in Japan
SoftBank and Tempus AI join forces to enhance healthcare in Japan with AI-driven solutions.
1–2 minutes
TOP STORIES
Obama stresses Democrats must prioritize AI safety and economic strategy …
Amodei’s call for caution in AI development highlights the need for safety and alignment …
Sony Music and Warner Music have sued Anthropic, accusing it of copyright infringement in AI training …
Huang believes Nvidia’s position in AI will lead to another year of record growth …
Anthropic’s report reveals a surge in distillation attacks by Chinese AI firms on U.S. models …
AI agents’ autonomy poses significant risks, as demonstrated by a recent breach …
